APO Research
Talk to an analyst

APO RESEARCH · REPORT

Depression-MDD Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Depression-MDD Drugs Market Outlook and Growth Opportunities 2026

31 December 2025196 pages

Choose your research edition.

Industry ResearchDepression-MDD Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Depression-MDD Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Depression-MDD Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Depression-MDD Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Depression-MDD Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Depression-MDD Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Depression-MDD Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Depression-MDD Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Depression-MDD Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Depression-MDD Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Depression-MDD Drugs market include Merck, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Reviva Pharmaceuticals Holdings, Janssen Pharmaceuticals and H. Lundbeck, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Depression-MDD Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Depression-MDD Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Depression-MDD Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Depression-MDD Drugs market.

Depression-MDD Drugs Segment by Company

Merck

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

Teva Pharmaceutical Industries

Reviva Pharmaceuticals Holdings

Janssen Pharmaceuticals

H. Lundbeck

Bristol-Myers Squibb

Depression-MDD Drugs Segment by Type

Selective Serotonin Reuptake Inhibitors,

Tricyclic Antidepressants

Atypical Antidepressants

Serotonin & Norepinephrine Reuptake Inhibitors

Depression-MDD Drugs Segment by Application

Online Pharmacy

Pharmacy

Hospital

Other

Depression-MDD Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Depression-MDD Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Depression-MDD Drugs key companies, revenue, market share, and recent developments.

3. To split the Depression-MDD Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Depression-MDD Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Depression-MDD Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Depression-MDD Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression-MDD Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Depression-MDD Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression-MDD Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Depression-MDD Drugs industry.

Chapter 3: Detailed analysis of Depression-MDD Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Depression-MDD Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Depression-MDD Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Depression-MDD Drugs Industry Trends Table 2. Depression-MDD Drugs Industry Drivers Table 3. Depression-MDD Drugs Industry Opportunities and Challenges Table 4. Depression-MDD Drugs Industry Restraints Table 5. Global Depression-MDD Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Depression-MDD Drugs Revenue Share by Company (2021-2026) Table 7. Global Depression-MDD Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Depression-MDD Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Depression-MDD Drugs Company, Product Type & Application Table 10. Global Depression-MDD Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Depression-MDD Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Selective Serotonin Reuptake Inhibitors, Table 15. Significant Companies of Tricyclic Antidepressants Table 16. Significant Companies of Atypical Antidepressants Table 17. Significant Companies of Serotonin & Norepinephrine Reuptake Inhibitors Table 18. Global Depression-MDD Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Depression-MDD Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Depression-MDD Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Depression-MDD Drugs Sales Value Share by Type (2021-2026) Table 22. Global Depression-MDD Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Online Pharmacy Table 24. Significant Companies of Pharmacy Table 25. Significant Companies of Hospital Table 26. Significant Companies of Other Table 27. Global Depression-MDD Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Depression-MDD Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Depression-MDD Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Depression-MDD Drugs Sales Value Share by Application (2021-2026) Table 31. Global Depression-MDD Drugs Sales Value Share by Application (2027-2032) Table 32. Global Depression-MDD Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Depression-MDD Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Depression-MDD Drugs Sales Value Share by Region (2021-2026) Table 35. Global Depression-MDD Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Depression-MDD Drugs Sales Value Share by Region (2027-2032) Table 37. Global Depression-MDD Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Depression-MDD Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Depression-MDD Drugs Sales Value Market Share by Country (2021-2026) Table 40. Global Depression-MDD Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Depression-MDD Drugs Sales Value Market Share by Country (2027-2032) Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Merck Depression-MDD Drugs Product Portfolio Table 46. Merck Recent Development Table 47. Eli Lilly Company Information Table 48. Eli Lilly Business Overview Table 49. Eli Lilly Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Eli Lilly Depression-MDD Drugs Product Portfolio Table 51. Eli Lilly Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Pfizer Depression-MDD Drugs Product Portfolio Table 56. Pfizer Recent Development Table 57. GlaxoSmithKline Company Information Table 58. GlaxoSmithKline Business Overview Table 59. GlaxoSmithKline Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. GlaxoSmithKline Depression-MDD Drugs Product Portfolio Table 61. GlaxoSmithKline Recent Development Table 62. AstraZeneca Company Information Table 63. AstraZeneca Business Overview Table 64. AstraZeneca Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. AstraZeneca Depression-MDD Drugs Product Portfolio Table 66. AstraZeneca Recent Development Table 67. Teva Pharmaceutical Industries Company Information Table 68. Teva Pharmaceutical Industries Business Overview Table 69. Teva Pharmaceutical Industries Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Teva Pharmaceutical Industries Depression-MDD Drugs Product Portfolio Table 71. Teva Pharmaceutical Industries Recent Development Table 72. Reviva Pharmaceuticals Holdings Company Information Table 73. Reviva Pharmaceuticals Holdings Business Overview Table 74. Reviva Pharmaceuticals Holdings Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Reviva Pharmaceuticals Holdings Depression-MDD Drugs Product Portfolio Table 76. Reviva Pharmaceuticals Holdings Recent Development Table 77. Janssen Pharmaceuticals Company Information Table 78. Janssen Pharmaceuticals Business Overview Table 79. Janssen Pharmaceuticals Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Janssen Pharmaceuticals Depression-MDD Drugs Product Portfolio Table 81. Janssen Pharmaceuticals Recent Development Table 82. H. Lundbeck Company Information Table 83. H. Lundbeck Business Overview Table 84. H. Lundbeck Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. H. Lundbeck Depression-MDD Drugs Product Portfolio Table 86. H. Lundbeck Recent Development Table 87. Bristol-Myers Squibb Company Information Table 88. Bristol-Myers Squibb Business Overview Table 89. Bristol-Myers Squibb Depression-MDD Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Depression-MDD Drugs Product Portfolio Table 91. Bristol-Myers Squibb Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Depression-MDD Drugs Product Image Figure 2. Global Depression-MDD Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Depression-MDD Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Depression-MDD Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Selective Serotonin Reuptake Inhibitors, Image Figure 8. Tricyclic Antidepressants Image Figure 9. Atypical Antidepressants Image Figure 10. Serotonin & Norepinephrine Reuptake Inhibitors Image Figure 11. Global Depression-MDD Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Depression-MDD Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Depression-MDD Drugs Sales Value Share by Type (2021-2032) Figure 14. Online Pharmacy Image Figure 15. Pharmacy Image Figure 16. Hospital Image Figure 17. Other Image Figure 18. Global Depression-MDD Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Depression-MDD Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Depression-MDD Drugs Sales Value Share by Application (2021-2032) Figure 21. Global Depression-MDD Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Depression-MDD Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Depression-MDD Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. North America Depression-MDD Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Depression-MDD Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Depression-MDD Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Depression-MDD Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Depression-MDD Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Depression-MDD Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. South America Depression-MDD Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Depression-MDD Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Depression-MDD Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Depression-MDD Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Selective Serotonin Reuptake Inhibitors,
  • Tricyclic Antidepressants
  • Atypical Antidepressants
  • Serotonin & Norepinephrine Reuptake Inhibitors
Applications
  • Online Pharmacy
  • Pharmacy
  • Hospital
  • Other
Companies covered
  • Merck
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Teva Pharmaceutical Industries
  • Reviva Pharmaceuticals Holdings
  • Janssen Pharmaceuticals
  • H. Lundbeck
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Depression-MDD Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Depression-MDD Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Depression-MDD Drugs Market Dynamics
  1. 2.1 Depression-MDD Drugs Industry Trends
  2. 2.2 Depression-MDD Drugs Industry Drivers
  3. 2.3 Depression-MDD Drugs Industry Opportunities and Challenges
  4. 2.4 Depression-MDD Drugs Industry Restraints
3 Depression-MDD Drugs Market by Company
  1. 3.1 Global Depression-MDD Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Depression-MDD Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Depression-MDD Drugs Company Ranking (2024-2026)
  4. 3.4 Global Depression-MDD Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Depression-MDD Drugs Company Product Type and Application
  6. 3.6 Global Depression-MDD Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Depression-MDD Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Depression-MDD Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Depression-MDD Drugs Market by Type
  1. 4.1 Depression-MDD Drugs Type Introduction
  2. 4.1.1 Selective Serotonin Reuptake Inhibitors,
  3. 4.1.2 Tricyclic Antidepressants
  4. 4.1.3 Atypical Antidepressants
  5. 4.1.4 Serotonin & Norepinephrine Reuptake Inhibitors
  6. 4.2 Global Depression-MDD Drugs Sales Value by Type
  7. 4.2.1 Global Depression-MDD Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Depression-MDD Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Depression-MDD Drugs Sales Value Share by Type (2021-2032)
5 Depression-MDD Drugs Market by Application
  1. 5.1 Depression-MDD Drugs Application Introduction
  2. 5.1.1 Online Pharmacy
  3. 5.1.2 Pharmacy
  4. 5.1.3 Hospital
  5. 5.1.4 Other
  6. 5.2 Global Depression-MDD Drugs Sales Value by Application
  7. 5.2.1 Global Depression-MDD Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Depression-MDD Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Depression-MDD Drugs Sales Value Share by Application (2021-2032)
6 Depression-MDD Drugs Regional Value Analysis
  1. 6.1 Global Depression-MDD Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Depression-MDD Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Depression-MDD Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Depression-MDD Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Depression-MDD Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Depression-MDD Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Depression-MDD Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Depression-MDD Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Depression-MDD Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Depression-MDD Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Depression-MDD Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Depression-MDD Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Depression-MDD Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Depression-MDD Drugs Sales Value Share by Country, 2025 VS 2032
7 Depression-MDD Drugs Country-level Value Analysis
  1. 7.1 Global Depression-MDD Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Depression-MDD Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Depression-MDD Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Depression-MDD Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Depression-MDD Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Depression-MDD Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Depression-MDD Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Depression-MDD Drugs Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Depression-MDD Drugs Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Depression-MDD Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Depression-MDD Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Depression-MDD Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Teva Pharmaceutical Industries
  32. 8.6.1 Teva Pharmaceutical Industries Company Information
  33. 8.6.2 Teva Pharmaceutical Industries Business Overview
  34. 8.6.3 Teva Pharmaceutical Industries Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Pharmaceutical Industries Depression-MDD Drugs Product Portfolio
  36. 8.6.5 Teva Pharmaceutical Industries Recent Developments
  37. 8.7 Reviva Pharmaceuticals Holdings
  38. 8.7.1 Reviva Pharmaceuticals Holdings Company Information
  39. 8.7.2 Reviva Pharmaceuticals Holdings Business Overview
  40. 8.7.3 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Product Portfolio
  42. 8.7.5 Reviva Pharmaceuticals Holdings Recent Developments
  43. 8.8 Janssen Pharmaceuticals
  44. 8.8.1 Janssen Pharmaceuticals Company Information
  45. 8.8.2 Janssen Pharmaceuticals Business Overview
  46. 8.8.3 Janssen Pharmaceuticals Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Janssen Pharmaceuticals Depression-MDD Drugs Product Portfolio
  48. 8.8.5 Janssen Pharmaceuticals Recent Developments
  49. 8.9 H. Lundbeck
  50. 8.9.1 H. Lundbeck Company Information
  51. 8.9.2 H. Lundbeck Business Overview
  52. 8.9.3 H. Lundbeck Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 H. Lundbeck Depression-MDD Drugs Product Portfolio
  54. 8.9.5 H. Lundbeck Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Depression-MDD Drugs Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst